Almost half (47%) of heart attack and stroke survivors don’t know their LDL or “bad cholesterol” number. That’s according to a recent American Heart Association
Last fall’s virus tripledemic is giving way to this year’s three-vaccine season. And the Department of Health and Human Services says it is pulling out
AstraZeneca is the latest pharma company to challenge the Inflation Reduction Act in court, this time zeroing in on the law’s provisions around orphan drugs.
Merck revealed Friday it started up its first late-stage clinical program for an oral PCSK9 inhibitor for cholesterol. The program is currently enrolling participants in
Merck and Eisai announced Friday morning that they plan to close a Phase III study of the combination of Keytruda and Eisai’s tyrosine kinase inhibitor
A Phase III-stage radiopharmaceuticals biotech has filed to go public a little over a week before bankers and industry watchers expect a slight post-Labor Day
→ Jürgen Eckhardt’s responsibilities at Bayer will expand on Sept. 1, as he becomes the head of business development & licensing/open innovation for the German
On the back of Sandoz’s FDA approval for the first-ever natalizumab biosimilar, branded as Tyruko, Biogen now has a formidable multiple sclerosis market competitor for
Novo Nordisk’s GLP-1 Wegovy has shown cardiovascular benefit again, this time in the Phase III STEP HFpEF trial, on top of the expected weight loss,
AMSTERDAM — Anti-inflammatory colchicine (Lodoco) given perioperatively around major non-cardiac thoracic surgery did not cut atrial fibrillation (Afib) or myocardial injury complications, the COP-AF trial